Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Segment Reporting Information [Line Items]
Revenue		$ 41,873	$ 37,647
Operating expenses		90,635	94,840
Adjusted EBITDA	[1]	(28,180)	(37,098)
Net loss		(47,533)	(57,700)
Net loss attributable to noncontrolling interest		26	1
Net loss attributable to Adaptive Biotechnologies Corporation		(47,507)	(57,699)
Interest and other income, net		(4,222)	(3,024)
Interest expense	[2]	2,993	3,531
Depreciation and amortization expense		5,214	5,423
Restructuring expense		1,044
Share-based compensation expense	[3]	14,298	14,671
Operating Segments | MRD
Segment Reporting Information [Line Items]
Revenue		32,626	21,427
Operating expenses		59,886	56,025
Adjusted EBITDA	[1]	(17,259)	(26,386)
Net loss		(27,260)	(34,597)
Net loss attributable to Adaptive Biotechnologies Corporation		(27,260)	(34,597)
Depreciation and amortization expense		2,701	2,056
Restructuring expense		467
Share-based compensation expense	[3]	6,833	6,155
Operating Segments | IM
Segment Reporting Information [Line Items]
Revenue		9,247	16,220
Operating expenses		23,841	31,672
Adjusted EBITDA	[1]	(6,927)	(7,427)
Net loss		(14,593)	(15,452)
Net loss attributable to Adaptive Biotechnologies Corporation		(14,593)	(15,452)
Depreciation and amortization expense		2,082	2,753
Restructuring expense		577
Share-based compensation expense	[3]	5,007	5,272
Unallocated Corporate
Segment Reporting Information [Line Items]
Operating expenses		6,908	7,143
Adjusted EBITDA	[1]	(3,994)	(3,285)
Net loss		(5,680)	(7,651)
Net loss attributable to noncontrolling interest		26	1
Net loss attributable to Adaptive Biotechnologies Corporation		(5,654)	(7,650)
Interest and other income, net		(4,222)	(3,024)
Interest expense	[2]	2,993	3,531
Depreciation and amortization expense		431	614
Share-based compensation expense	[3]	$ 2,458	$ 3,244

[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation for how it is calculated and used by management.

[2] Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 8, Revenue Interest Purchase Agreement for details on the Purchase Agreement.

[3] Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 11, Equity Incentive Plans for details on our share-based compensation expense.